IACT Health - VHC

Columbus, Georgia 31904

0 studies enrolling now · 3 studies all time

What they study most

Atopic Dermatitis, COVID-19

Studies at this site

• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) — Completed
• A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness — Completed